Introduction {#S1}
============

Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) belonging to the family Flaviviridae and genus Flavivirus. As a single-stranded positive RNA virus, the genome of ZIKV is approximately 10 kb and encodes three structural proteins and seven non-structural proteins ([@B116]). In 1947, ZIKV was discovered and isolated from a sentinel Rhesus monkey in the Zika Forest of Uganda ([@B25]). However, it was only in 2015 that the first outbreak of ZIKV-caused diseases was reported in Brazil ([@B86]) with more than one million cases. Since then, it rapidly spread to 84 countries around world, particularly in South America, rendering ZIKV a public health threat ([@B36]; [Figure 1](#F1){ref-type="fig"}).

![Summary of ZIKV morbidity statistics with country- and quarter-level panel data. The deeper the color, the higher the number of infected people.](fmicb-10-02725-g001){#F1}

Mild symptoms include fever, rash, headache, and joint pain, but the major concern involves the potential for severe neurological disorders, such as microcephaly, neurological disorders in newborns, meningo-encephalitis, Guillain--Barré syndrome, myelitis, and ocular abnormalities ([@B5]). Until now, neither a specific antiviral drug nor a vaccine has been developed to prevent or cure ZIKV infection. However, several well-characterized drug targets encoded by the virus, or presented in host cells, may help us prevent or treat ZIKV infection. In this review, we focus on current progress on the research and development of small-molecule ZIKV inhibitors, either viral or host cell inhibitors, targeting different stages of the ZIKV life cycle. Such data are essential to the design of drugs and drug delivery modalities against ZIKV and related viruses.

ZIKV Life Cycle and Potential Targets for the Development of Small-Molecule Inhibitors Against ZIKV Infection {#S2}
=============================================================================================================

The life cycle of ZIKV can be divided into four stages, including virus entry, genome replication, virus assembly, and release. Mature ZIKV particles first adhere to host cells by interacting with specific receptors on host cells, such as DC-SIGN, AXL, Tyro, and TIM-1 ([@B73]; [@B78]; [@B67]). Several proteins, including DC-SIGN and TIM as well as some TAM proteins that belong to the phosphatidylserine receptor family, have been reported to act as receptors for entry of dengue virus (DENV)([@B62]; [@B66]; [@B85]). To determine whether these receptors are also involved in ZIKV entry, a series of transfected HEK293T cells expressing DC-SIGN, TIM-1, or a TAM family member (AXL or Tyro3) could be infected by ZIKV at varying degrees ([@B35]). DC-SIGN consists of group II (calcium-dependent with single carbohydrate recognition domain) transmembrane C-type lectins that can interact through their carbohydrate recognition domains to bind carbohydrates to viral protein E ([@B123]; [@B20]). DC-SIGN also plays an important role in flavivirus binding and the infection of myeloid cells ([@B75]) as it mediates attachment of viral particles on the cell surface and facilitates their interaction with primary receptors on the host cell ([@B16]; [@B34]). Tyro3 and AXL belong to the TAM family, a group of three receptor protein tryrosine kinases that mediate the clearance of apoptotic cells ([@B51]). AXL is expressed in astrocytes and microglia in the human brain development and mediates ZIKV infection of glial cells ([@B78]; [@B67]). AXL consisting of two different Gas6-binding epitopes, including the N-terminal Ig-like domain, and a second Ig domain exists in the dimeric form. Gas6, which is the ligand of AXL, connects ZIKV to glial cells. TIM-1, which is abundant on Th-2 T cells, mucosal epithelial cells, and mast cells, mediates the attachment of ZIKV particles on the cell surface to facilitate their interaction with AXL as well as the subsequent infection ([@B35]). The availability of different entry receptors is likely to provide an evolutionary advantage for the virus, and, as a result, the virus is able to infect a wide range of human host cells.

After binding with host cells, ZIKV is internalized by clathrin-mediated endocytosis and traffics to Rab5^+^ endosomes ([@B114]; [@B71]). In the process of entering the host cell, AXL kinase activity is activated by the ZIKV/Gas6 complex, which downregulates interferon signaling and promotes infection. Then, the endosome membrane and virus envelope (E) are fused under the acidic environment of the endosome. The viral genomic RNA is then released into the cytoplasm ([@B114]; [@B71]). In the process of virus entry, some inhibitors can block viral attachment, endocytosis, and fusion. The proteins E on ZIKV and the DC-SIGN, AXL, Tyro, and TIM-1 entry/adhesion factors on the host cell are involved in viral attachment, endocytosis, fusion, and entry ([@B37]; [@B38]; [@B99]). They all therefore serve as targets for the development of small molecule inhibitors. After virus entry, the genome of ZIKV is translated and cleaved into three structural proteins, including Capsid (C), Precursor of the membrane protein (prM)/membrane protein (M), Envelope (E), as well as seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The NS1 protein is related to flavivirus replication and virion maturation. The NS2B protein activates the active region of the NS3 protein and forms an NS2B-NS3 complex with the NS3 protein to exert proteolytic enzyme activity. The NS4A and NS4B proteins comprise the endoplasmic reticulum (ER)-associated replication complex. The NS5 protein contains the C-terminal RNA-dependent RNA polymerase domain and the N-terminal methyltransferase domain, which cooperate during the initiation and extension of RNA synthesis. In addition, the NS5 protein is the largest NS protein in molecular weight and the most highly conserved. Then RNA is replicated with the actions of NS1, NS2B-NS3 proteinase and NS3 helicase, NS5 methyltransferase, and NS5RdRp. Viruses encode their own essential proteases in the viral replication process, which can serve as targets for therapeutic intervention. The methylated (+) ssRNA, C, E, and prM proteins are assembled to form immature virions in the ER. Then, the ER vesicles transport the virus particles to Golgi apparatus, and the virus particles undergo surface polysaccharide modification, prM-E protein trimer rearrangement, and Furin protease cleavage prM while mature virus particles with a smooth surface are produced, finally leaving the host cell by exocytosis as mature virus ([Figure 2](#F2){ref-type="fig"}; [@B114]; [@B71]). Some small molecule inhibitors that target the C protein or inhibit viral capsid formation are able to affect viral assembly and release. Meanwhile, correct expression and processing of nascent proteins in host cells are essential for efficient viral replication. Several host proteins, such as ER membrane complex, α-glucosidase, cyclophilin, and proteasome elements, are responsible for monitoring proper protein synthesis, folding, and degradation. Impairment of these functions results in reduced viral assembly and budding. Therefore, these host proteins may also serve as targets for the development of small molecule ZIKV inhibitors.

![Zika virus infectious life cycle: Host cell membrane receptors bind the E protein of the mature Zika virion, triggering endocytosis. The acidic environment of the endosome induces fusion of the host endosome membrane with the viral envelope and the release of the RNA genome. The RNA is translated into a polyprotein complex, which is cleaved by the host and viral proteases in the ER lumen and cytoplasm, respectively. Following translation, a replication complex is assembled and associated with virus induced membranes where viral replication takes place. The methylated (+) ssRNA, C, E, and prM proteins assemble to form immature virions in the endoplasmic reticulum (ER). The immature virions bud out of the ER into the Golgi apparatus, and they then mature in the trans-Golgi network that are released by exocytosis. In the orange boxes are the names of the compounds that can inhibit the marked steps of the virus lifecycle and that are evaluated in animal models or clinical trials.](fmicb-10-02725-g002){#F2}

Most antiviral drugs are small-molecule inhibitors that target different stages of the viral life cycle by interacting with virus or host proteins critical for virus replication ([@B22]). For example, inhibiting AXL function can protect cells from infection and, thus, may be a potential target for the production of entry inhibitors. However, destroying AXL function may also have many adverse consequences ([@B78]). In addition, the proteases crucial for ZIKV replication are potential targets for developing ZIKV replication inhibitors. Therefore, more effective and appropriate targets need to be developed by researchers.

Current Small-Molecule Inhibitors Against ZIKV Infection and Their Mechanisms of Action {#S3}
=======================================================================================

ZIKV Entry Inhibitors {#S3.SS1}
---------------------

### ZIKV Inhibitors Targeting Viral E Protein {#S3.SS1.SSS1}

The structure of ZIKV envelope protein (E protein) is similar to that of other flaviviruses, and it has three characteristic domains: a central β-barrel-shaped domain I, a Slender finger-like domain II, and a C-terminal immunoglobulin-like domain III ([@B21]). The recognition and binding of ZIKV E proteins to host cell receptors mark the beginning of ZIKV infection; therefore, some inhibitors designed for envelope proteins can effectively inhibit virus infection ([@B10]).

Small molecule inhibitors that specifically target the ZIKV E protein have been reported. Peptide Z2 ([Table 1](#T1){ref-type="table"}), derived from the stem region of the ZIKV E protein, inhibits vertical transmission of ZIKV in pregnant C57BL/6 mice and protects type I or type I/II interferon receptor-deficient mice against lethal ZIKV challenge ([@B120]). Peptide Z2 can interact with viral E proteins to form a membrane pore and disrupt the integrity of the viral membrane ([@B120]). ZINC33683341 \[[Figure 3](#F3){ref-type="fig"}(1); [@B31]\], which can bind with the ZIKV E protein, is preferential when compared with glycan and can block the formation of glycoside bonds between ZIKV and host Vero cells at the concentration of 100 μM ([Table 2](#T2){ref-type="table"}; [@B31]).

###### 

Zika virus peptide inhibitors.

  **Inhibitor**      **Sequence**     **Testing model**   **Cell lines**                 **IC~50~ (μM)**   **CC~50~ (μM)**   **References**
  ------------------ ---------------- ------------------- ------------------------------ ----------------- ----------------- ---------------------------------
  Peptide Z2         MAVLGDTAWDF      *in vitro*          BHK21 cells                    1.75 ± 0.13       --                [@B120]
                     GSVGGALNSLG                                                         3.69 ± 0.27                         
                     KGIHQIFGAAF                          Vero cells                                                         
  P5                 GQASNGVFVIH      *in vitro*          Vero cells                     3.27              --                [@B15]
                     WGKFDSFGIAV                                                                                             
  Ev37               GLINEKKVQQYLDE   *in vitro*          Huh-7 cells                    --                --                [@B56]
                     KLPNGVVKGALKSL                                                                                          
                     VHKAAKNQNLCAF                                                                                           
                     NVDTVGMCDADCK                                                                                           
                     RQGKAKGVCHGT                                                                                            
                     KCKCDVELSYKK                                                                                            
  Aprotinin          --               *in vitro*          --                             0.07 ± 0.012      --                [@B100]
  Acyl-KR-aldehyde   --               --                  --                             0.208             --                [@B55]
  AH-D peptide       SGSWLRDVWDWIC    *in vivo*           In mouse                       0.0119            --                [@B18], [@B40]
                     TVLTDFKTWLQSKL                                                                                          
  FFAAP              FFAAP            *in vitro*          Human JEG-3 cells Vero cells                     --                [@B64], [@B24], [@B44], [@B110]
  ZMP STE24          --               *in vitro*          T98-G cells                    --                --                [@B33]

![Chemical structures of ZIKV small-molecule inhibitors.](fmicb-10-02725-g003){#F3}

###### 

Zika virus entry inhibitors.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Number of chemical structures in [Figure 3](#F3){ref-type="fig"}**   **Inhibitor**           **Testing model**   **Cell lines**                          **IC~50~ (μM)**   **CC~50\ (~μM)**   **References**
  ---------------------------------------------------------------------- ----------------------- ------------------- --------------------------------------- ----------------- ------------------ -----------------------------------------
  1                                                                      Tweezer CLR01           *in vitro*          Vero E6 cells                           8.2               --                 [@B6], [@B14], [@B8], [@B61], [@B94]

  2                                                                      ZINC33683341            *in vitro*          Vero cells                              --                --                 [@B31]

  3                                                                      Baicalin                *in vitro*          Vero cells                              14                553                [@B82]

  4                                                                      EGCG                    *in vitro*          Vero E6 cells                           --                --                 [@B103], [@B39], [@B74], [@B12], [@B13]

  5                                                                      Curcumin                *in vitro*          Huh-7 cells                             1.90              11.6               [@B102], [@B72], [@B77], [@B96]

  6                                                                      Nanchangmycin           *in vitro*          Human U2OS cells                        0.1               7                  [@B60], [@B89], [@B93]

                                                                                                                     Human HBMEC cells                       0.4               \>10               

                                                                                                                     Human JEG-3 cells                       0.97              6.10               

  7                                                                      Chloroquine             *in vitro*          Huh-7 cells                             1.72              --                 [@B53]

                                                                                                 *in vivo*           Vero cells; BALB/c mice and A129 mice   4.15                                 

  8                                                                      Suramin                 *in vitro*          Vero cells                              39.8              1900               [@B1], [@B19]

  9                                                                      25-hydroxycholesterol   *in vitro*\         Vero cells; BALB/c mice and A129 mice   0.188             --                 [@B52]
                                                                                                 *in vivo*                                                                                        

  10                                                                     Niclosamide             *in vitro*          A549 cells\                             12.3 ± 0.6\       4.8 ± 1.0          [@B3], [@B55], [@B118], [@B55]
                                                                                                                     SNB-19 cells                            1.72                                 

  11                                                                     Cabozantinib            *in vitro*          Human U2OS cells                        0.2               \>10               [@B93]

  12                                                                     BMS-777607              *in vitro*          Human U2OS cells                        0.6               \>10               [@B93]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Some small molecule inhibitors that non-specifically target the ZIKV E protein were also active against other medically relevant viruses that use a similar route of entry. P5, a peptide extracted from the stem of Japanese encephalitis virus E protein, can inhibit ZIKV entry into host cells by changing the conformation of the E protein under low pH. The hydrophobicity of the last seven amino acid residues is also considered to be the key to the binding of the viral membrane ([Table 1](#T1){ref-type="table"}; [@B15]). *In vivo* experiments in mice highly sensitive to ZIKV showed that P5 can inhibit spermatic tubule disorder and reproductive epithelial cell degeneration while also alleviating the circulatory constriction of blood vessels ([@B15]).

The molecular tweezer CLR01, which has potent inhibition activity to envelope viruses, can inhibit ZIKV strains in Vero E6 cells \[[Figure 3](#F3){ref-type="fig"}(2) and [Table 2](#T2){ref-type="table"}\] by destroying the intact membrane structure that is enriched with high levels of sphingolipid and cholesterol ([@B6]; [@B14]; [@B8]; [@B61]; [@B94]). In addition, it can inhibit ZIKV infection in semen, urine, saliva, cerebrospinal fluid, and other body fluids, but lose activity in serum ([@B94]). Some studies have attributed this effect to the relatively high protein content in serum ([@B94]).

Baicalin \[[Figure 3](#F3){ref-type="fig"}(3)\], which has high affinity to the virus E protein and low toxicity to cells, can inhibit ZIKV from entering cells ([Table 2](#T2){ref-type="table"}; [@B82]). (-)-Epigallocatechin gallate (EGCG), a polyphenol from green tea, was shown to inhibit many viruses \[[Figure 3](#F3){ref-type="fig"}(4) and [Table 2](#T2){ref-type="table"}; [@B39]; [@B74]; [@B12]\]. Accordingly, EGCG can bind to the ZIKV E protein to block ZIKV entry into host cells ([@B103]). However, EGCG contains the catechol group that may non-specifically inhibit many different targets ([@B71]). Curcumin can inhibit ZIKV infection in a dose-dependent manner \[[Figure 3](#F3){ref-type="fig"}(5)\]. It is not only a replication inhibitor of ZIKV, but also prevents the viral E protein from binding to the cell surface ([@B72]; [@B96]). In Vero cells, the IC~50~ and CC~50~ value of curcumin inhibiting ZIKV is 1.90 and 11.6 μM, respectively ([Table 2](#T2){ref-type="table"}; [@B72]). Nanchangmycin \[[Figure 3](#F3){ref-type="fig"}(6)\], produced by Streptomyces nanchang fermentation, can inhibit gram-positive bacteria and has insecticidal and antibacterial activities against poultry *in vitro* ([@B93]). For Zika virus, Nanchangmycin can inhibit ZIKV infection by blocking clathrin-mediated endocytosis with IC~50~s between 0.1 and 0.4 μM, and it has low toxicity in this range ([Table 2](#T2){ref-type="table"}) in human U2OS cells, human brain microvascular endothelial cells (HBMEC), and human Jeg-3 cells, respectively ([@B93]).

### ZIKV Inhibitors Targeting Endosome {#S3.SS1.SSS2}

Endosomes provide a transport route for ZIKV to enter host cells. Ev37 ([Table 1](#T1){ref-type="table"}), an endosomal scorpion peptide inhibitor, can effectively inhibit ZIKV infection at a non-cytotoxic concentration ([@B56]). Ev37 is a broad-spectrum and specific antiviral peptide, which can alkalize the pH value of endosomes, inhibit the release of a viral genome, and prevent it from entering the cytoplasm, thus blocking ZIKV infection ([@B56]). In Huh-7 cells, Ev37 can reduce 87% of ZIKV infection at a concentration of 10 μM ([@B56]). Chloroquine ([@B52]), Suramin ([@B1]), and 25-hydroxycholesterol \[[Figure 3](#F3){ref-type="fig"}(7--9) and [Table 2](#T2){ref-type="table"}; [@B52]) demonstrated their ability to inhibit ZIKV internalization *in vitro*. Niclosamide is an FDA-approved drug broadly used in the treatment of intestinal helminthiasis \[[Figure 3](#F3){ref-type="fig"}(10) and [Table 2](#T2){ref-type="table"}\]. It can prevent endosomal acidification, but the mechanism is not fully elucidated ([@B32]; [@B43]).

### ZIKV Inhibitors Targeting AXL {#S3.SS1.SSS3}

AXL is a tyrosine kinase receptor (TKR), which can mediate viral attachment to host cells. Therefore, it is necessary to inhibit primary cells with high AXL content ([@B78]). Cabozantinib and BMS-777607 are two kinase inhibitors that inhibit AXL \[[Figure 3](#F3){ref-type="fig"}(11,12); [@B93]\]. In human U2OS cells, their IC~50~ values are 0.2 and 0.6 μM, respectively, and the CC~50~ values are greater than 10 μM ([Table 2](#T2){ref-type="table"}; [@B93]). However, the experiments showed that AXL inhibitors were effective only on AXL-rich cells ([@B93]), indicating that the effect is cell-type specific.

Although several studies proclaimed that AXL is a receptor for ZIKV entry *in vitro*, a few reports showed the opposite results. The genetic ablation of AXL has no significant effect on ZIKV entry or ZIKV-mediated cell death in human-induced pluripotent stem cell (iPSC)-derived NPCs or cerebral organoids ([@B79]; [@B93]) reported that Jeg-3 cells that show no detectable AXL expression were highly permissive to ZIKV infection, suggesting that AXL may not be essential for ZIKV infection. This hypothesis is corroborated by an *in vivo* study ([@B115]). Notably, the AXL receptor supports neural stem cell survival, proliferation and neurogenesis ([@B41]), and signaling; the AXL also regulates blood--brain barrier (BBB) integrity in the context of viral infections ([@B69]). Therefore, while blocking AXL may protect against ZIKV infecting or viral replication, perturbation of AXL function may also have multiple adverse consequences. Therefore, the use of the AXL receptor as an idea target for the inhibition of Zika virus infection remains to be confirmed. Efforts to elucidate the molecular mechanism for ZIKV infection, through both targeted TAM receptor knockout studies and unbiased screening for other binding factors that render cells resistant to ZIKV, will lead to the identification of new targets for development of anti-ZIKV therapeutics.

ZIKV Replication Inhibitors {#S3.SS2}
---------------------------

### ZIKV Inhibitors Targeting NS2B-NS3 Protease {#S3.SS2.SSS1}

NS2B-NS3 protease of Zika virus plays an essential role in ZIKV replication and maturation. NS2B-NS3 processes the viral non-structural proteins from the viral polyprotein into individual proteins. NS2B-NS3 is a serine protease that consists of the N-terminal domain of NS3 and a short cofactor from the hydrophilic core sequence of NS2B. Like the NS4A cofactor of the HCV protease, Flavivirus NS3 is inactive without the NS2B co-factor ([@B28]).

Three different ZIKV NS2B-NS3 protease (ZIKVpro) constructs have been proposed. First, a covalent G~4~SG~4~ linker peptide between NS2B and NS3 (gZiPro) construct was adopted based on previous West Nile and DENV protease constructs ([@B50]). The other two constructs include one bivalent protease consisting of two separate polypeptide NS2B and NS3 (bZiPro) ([@B124]) and one with its own NS2B C-terminal peptide (TGKR) binding NS2B to NS3 (eZiPro) ([@B87]). Remarkably, the single-chain enzyme gZiPro with an artificial linker that is commonly applied for the constructs of other flaviviruses has been widely used for screening inhibitors. Aprotinin, a 58 amino acid bovine trypsin inhibitor, inhibits ZIKV NS2B-NS3 protease with an IC~50~ of 70 nM by blocking the interactions of NS3 and NS2B, as predicted by molecular modeling studies ([Table 1](#T1){ref-type="table"}; [@B100]). By using structure-based virtual screening, novobiocin and lopinavir-ritonavir can inhibit ZIKV NS2B-NS3 protease activity by using molecular docking analysis \[[Figure 3](#F3){ref-type="fig"}(13--15); [@B121]\]. Novobiocin, an aminocoumarin antibiotic, inhibited protease activity by highly stable binding with ZIKV NS2B-NS3 protease to diminish its catalytic efficiency ([@B46]; [@B121]). It can inhibit ZIKV replication with an IC~50~ of 26.12 ± 0.33 μg/ml and CC~50~ of 850.50 μg/ml in Vero cells and an IC~50~ of 38.14 ± 4.53 μg/ml and CC~50~ of 1103.18 μg/ml in Huh-7 cells ([Table 3](#T3){ref-type="table"}; [@B121]). Lopinavir-ritonavir can inhibit protease activity of ZIKV replication with an IC~50~ of 4.78 ± 0.41 μg/ml and CC~50~ of 30.00 μg/ml in Vero cells and an IC~50~ of 3.31 ± 0.36 μg/ml CC~50~ of 32.12 μg/ml in Huh-7 cells ([Table 3](#T3){ref-type="table"}; [@B121]).

###### 

Zika virus replication inhibitors.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Number of chemical structures in [Figure 3](#F3){ref-type="fig"}**   **Inhibitor**                                                          **Testing model**   **Cell lines**                               **IC~50~ (μM)**   **CC~50~ (μM)**   **References**
  ---------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------- -------------------------------------------- ----------------- ----------------- -----------------------------------------
  **Inhibitors targeting NS2B-NS3 protease**                                                                                                                                                                                                         

  13                                                                     Novobiocin                                                             *in vitro*          Vero cells                                   26.12 ± 0.33      850.50            [@B46], [@B121]

                                                                                                                                                                    Huh-7 cells                                  38.14 ± 4.53      1103.18           

  14,15                                                                  Lopinavir-ritonavir                                                    *in vitro*          Vero cells                                   4.78 ± 0.41       30.00             [@B121]

                                                                                                                                                                    Huh-7 cells                                  3.31 ± 0.36       32.12             

  16                                                                     Phenylacetyl-Lys-Lys-Arg-Gly-Gly-NH2                                   *in vitro*          --                                            1.2 ± 0.14       --                [@B84], [@B88], [@B76]

  17                                                                     4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-NH2                         *in vitro*          --                                           1.6 ± 0.14        --                [@B84], [@B88], [@B76]

  18                                                                     4-guanidinomethyl-phenylacetyl-Arg-Arg-Arg-4-amidinobenzylamide        *in vitro*          --                                           1.1 ± 0.07        --                [@B84], [@B88], [@B76]

  19                                                                     Hydrolysis product of phenylacetyl-Lys-Lys-Arg-Gly-Gly-NH2             *in vitro*          --                                           18.4 ± 1.9        --                [@B84], [@B88], [@B76]

  20                                                                     Hydrolysis product of 4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-NH2   *in vitro*          --                                           5.9 ± 0.55        --                [@B84], [@B88], [@B76]

  21                                                                     Bz-\[4-(CH2NH2)\]Phe-Arg- B(OH)2                                       *in vitro*          --                                           0.25              --                [@B77]

  22                                                                     Bz-(3-guanidinyl)Phe-Arg- B(OH)2                                       *in vitro*          --                                           1.9               --                [@B77]

  23                                                                     Bz-(4-guanidinyl)Phe-Arg- B(OH)2                                       *in vitro*          --                                           0.83              --                [@B77]

  24                                                                     4-tBuBz-(4-guanidinyl)Phe-Arg- B(OH)2                                  *in vitro*          --                                           2.1               --                [@B77]

  25                                                                     5-amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-yl benzoate         *in vitro*          BznKRR-AMC                                   1.5\              --                [@B125]
                                                                                                                                                                                                                  0.1                                

  26                                                                     Hydroxychloroquine                                                     *in vitro*          JEG3 cells                                   --                --                [@B48]

  27                                                                     Myricetin                                                              *in vitro*          --                                           1.26              --                [@B59], [@B96]

  28                                                                     Apigenin                                                               *in vitro*          --                                           56.32             --                [@B96]

  29                                                                     Isorhamnetin                                                           *in vitro*          --                                           15.46             --                [@B96]

  30                                                                     Temoporfin                                                             *in vitro*          A549 cells                                   1.1 ± 0.1         40.7 ± 0.7        [@B3], [@B55]

  31                                                                     Nitazoxanide                                                           *in vitro*          A549 cells                                   15.9 ± 0.9        77 ± 7.2          [@B3], [@B55]

  32                                                                     BAS 19192837                                                           --                  --                                           --                --                [@B95]

  33                                                                     Berberine                                                              *in vitro*          --                                           --                --                [@B97]

  34                                                                     Erythrosin B                                                           *in vitro*          A549 cells                                   0.62 ± 0.12       --                [@B49], [@B58]

  35                                                                     Luteolin                                                               *in vitro*          --                                           53 ± 1.3          --                [@B59]

  36                                                                     Astragalin                                                             *in vitro*          --                                           112 ± 5.5         --                [@B59]

  37                                                                     Rutin                                                                  *in vitro*          --                                           104 ± 2.9         --                [@B59]

  38                                                                     Epigallocatechin gallate                                               *in vitro*          --                                           87 ± 1.2          --                [@B59]

  39                                                                     Gallocatechin gallate                                                  *in vitro*          --                                           99 ± 1.8          --                [@B59]

  **Inhibitors targeting NS5**                                                                                                                                                                                                                       

  40                                                                     ZINC64717952                                                           *in vitro*          --                                           --                --                [@B92]

  41                                                                     ZINC39563464                                                           *in vitro*          --                                           --                --                [@B92]

  42                                                                     Baicalein                                                              *in vitro*          Vero cells                                   0.004             --                [@B122], [@B70], [@B42], [@B81], [@B82]

  43                                                                     DMB213                                                                 *in vitro*          Huh-7 cells                                  5.2               --                [@B117]

  44                                                                     *N*-(4-hydroxyphenyl) retinamide                                       *in vitro*          Vero cells                                   1.1 ± 0.4         --                [@B112]

                                                                                                                                                                                                                 1.2 ± 0.1                           

  45                                                                     7DMA                                                                   *in vitro*          Vero cells                                   20 ± 15           \>357             [@B80], [@B126]

                                                                                                                                                                                                                 9.6 ± 2.2                           

  46                                                                     Sofosbuvir                                                             *in vitro*          Huh-7 cells\                                 1 ∼ 5             \>200             [@B49], [@B58]
                                                                                                                                                                     Jar human placental choriocarcinoma cells                                       

  47                                                                     F3043-0013                                                             *in vitro*          Vero cells                                   4.8 ± 2.3         --                [@B105]

  48                                                                     F0922-0796                                                             *in vitro*          Vero cells                                   12.5 ± 7.4        --                [@B105]

  49                                                                     F1609-0442                                                             *in vitro*          Vero cells                                   17.5 ± 8.4        --                [@B105]

  50                                                                     F1750-0048                                                             *in vitro*          Vero cells                                   17.6 ± 3.1        --                [@B105]

  51                                                                     ZINC50166190                                                           *in vitro*          --                                           --                --                [@B101]

  52                                                                     2′-C-Me-UTP                                                            *in vitro*          --                                           5.78              --                [@B63]

  53                                                                     2′-F-2′-C-Me-UTP                                                       *in vitro*          --                                           90.76             --                [@B63]

  54                                                                     2′-C-ethynyl-UTP                                                       *in vitro*          --                                           0.46              --                [@B63]

  55                                                                     3′-dUTP                                                                *in vitro*          --                                           0.67              --                [@B63]

  56                                                                     Merimepodib (MMPD, VX-497)                                             *in vitro*          Huh-7 cells                                  0.6 ± 0.2         \>10              [@B107]

  57                                                                     Resiquimod                                                             *in vitro*          CHME3 cells.                                 --                --                [@B109]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Recently, Phoo et al. have shown that the glycine-rich artificial linker or "TGKR" peptide could introduce steric hindrance, resulting in the change of the inhibitor-binding mechanism ([@B87]). The wide-type NS2B and NS3pro domain are not covalently linked ([@B45]). bZiPro, which is closer to the native state, has higher activity and is more suitable for inhibitor screening than gZiPro and eZiPro because of its free active site being accessible to substrates or inhibitors ([@B23]; [@B87]; [@B98]). Acyl-KR-aldehyde, a dipeptide, can form a covalent bond with the Ser135 residue of NS3 and the KR residues occupy the S1 and S2 sites of NS3 ([@B55]). Acyl-KR-aldehyde can inhibit the bZiPro construct of NS2B-NS3 protease with an IC~50~ of 208 nM ([Table 1](#T1){ref-type="table"}; [@B55]). Nuclear magnetic resonance (NMR) spectroscopy demonstrated that the bZiPro construct of NS2B-NS3 and Acyl-KR-aldehyde can form a stable complex ([@B54]). The peptidomimetic inhibitors composed of a P1-P4 segment and different P1' residues, including Phenylacetyl-Lys-Lys-Arg-Gly-Gly-NH~2~, 4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-NH~2~, 4-guanidinomethyl-phenyl- acetyl-Arg-Arg-Arg-4-amidinobenzylamide, a hydrolysis product of phenylacetyl-Lys-Lys-Arg-Gly-Gly-NH2, and a hydrolysis product of 4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-NH2 \[[Figure 3](#F3){ref-type="fig"}(16--20)\], can inhibit ZIKV replication against the NS2B-NS3 protease of ZIKV with an IC~50~ of 1.2 ± 0.14, 1.6 ± 0.14, 1.1 ± 0.07 μM, and 18.4 ± 1.9, 5.9 ± 0.55 μM, respectively ([Table 3](#T3){ref-type="table"}; [@B88]). As non-competitive inhibitors, five macrocyclic peptides can act as ligands with high affinity and can be rapidly isolated for nearly any target by using display screening approaches, such as an mRNA display or phage display ([@B84]). These peptides can inhibit bZiPro constructs of NS2B-NS3 protease activity with an IC~50~ from 0.24 to 4.9 μM ([@B76]). AH-D peptide, a 27-mer amphipathic α-helical peptide, protects against lethal ZIKV infection with IC~50~ = 0.012 μM in primary neuronal cells, inhibits ZIKV infection in mouse brains, and preserves BBB integrity ([Table 1](#T1){ref-type="table"}; [@B18]; [@B40]). The AH-D peptide also significantly reduced viral loads in the serum, brain, spleen, and optical nerve throughout the course of infection ([@B40]). Four dipeptidic inhibitors have a C-terminal boronic acid moiety, including Bz-\[4-(CH2NH2)\]Phe-Arg-B(OH)~2~, Bz-(3-guani-dinyl)Phe-Arg-B(OH)~2~, Bz-(4-guani-dinyl)Phe- Arg-B(OH)~2~, and 4-tBuBz-(4-guanidinyl)Phe-Arg-B(OH)~2~ \[[Figure 3](#F3){ref-type="fig"}(21--24)\]. These compounds can inhibit ZIKV NS2B-NS3 protease activity with IC~50~ from 0.25 to 2.1 μM ([Table 3](#T3){ref-type="table"}; [@B77]).

Li Y. et al. have found that a pyrazole ester derivative, 5-amino-1-((4-methoxyphenyl)sulfonyl) -1H-pyrazol-3-yl benzoate \[[Figure 3](#F3){ref-type="fig"}(25)\], can inhibit ZIKV replication with an IC~50~ of 1.5 μM when benzoyl-Nle-Lys-Arg-Arg-aminomethylcoumarin (BznKRR-AMC) was used as a substrate ([Table 3](#T3){ref-type="table"}; [@B57]). The benzoyl group of this inhibitor forms a covalent bond with the side chain of catalytic residue S135 to stabilize the closed conformation of the ZIKV bZiPro construct of NS2B-NS3 protease ([@B57]). In addition, a derivative of pyrazole ester, 5-amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-yl benzoate, with an IC~50~ of 0.1 μM can interact in a manner similar to the compound \[[Figure 3](#F3){ref-type="fig"}(25)\] and strongly inhibit binary ZIKV bZiPro construct of NS2B-NS3 protease ([@B57]). Hydroxychloroquine \[[Figure 3](#F3){ref-type="fig"}(26)\], a drug already approved and used in pregnancy, can inhibit the bZiPro construct of NS2B-NS3 protease activity with an inhibition constant (Ki) of 92.34 ± 11.91 μM ([Table 3](#T3){ref-type="table"}; [@B48]).

Some natural products from edible plants, like myricetin, can inhibit ZIKV infection with an IC~50~ of 1.26 μM and an inhibitory constant of ZIKV NS2B-NS3 protease activity with *Ki* of 0.77 μM by establishing six hydrogen bonds with four Zika NS3pro residues: Lys73, Asn152, Gln74, and Gly124 \[[Figure 3](#F3){ref-type="fig"}(27) and [Table 3](#T3){ref-type="table"}; [@B96]\]. Apigenin inhibits ZIKV infection with an IC~50~ of 56.32 μM and inhibitory constant *Ki* of 34.02 μM \[[Figure 3](#F3){ref-type="fig"}(28) and [Table 3](#T3){ref-type="table"}; [@B96]\]. Isorhamnetin, also called 3′-Methylquercetin, can inhibit ZIKV infection with IC~50~ of 15.46 μM and *Ki* of 6.22 μM as well as Quercetin with IC~50~ of 2.42 μM and *Ki* of 1.12 μM \[[Figure 3](#F3){ref-type="fig"}(29) and [Table 3](#T3){ref-type="table"}; [@B96]). Structurally, isorhamnetin is a derivative of quercetin with a very similar molecular structure ([@B96]). In addition, curcumin \[[Figure 3](#F3){ref-type="fig"}(5) and [Table 2](#T2){ref-type="table"}\], a natural phenol with two aromatic rings linked by a heptadiene group, can inhibit ZIKV infection with IC~50~ of 3.45 μM and *Ki* of 2.61 μM, most likely by having bivalent binding sites ([@B102]; [@B96]). The introduction of a C-terminal boronic acid moiety into dipeptidic inhibitors can raise the affinity to target by a 1000-fold ([@B77]). However, curcumin, quercetin, and other flavonoids have shown themselves to be promiscuous inhibitors, e.g., via colloidal aggregation ([@B65]; [@B26]; [@B108]). Curcumin also contains reactive Michael acceptors, and quercetin has a catechol, a well-known PAINS substructure, which might make these compounds less favorable ([@B71]).

A total of 2,816 approved and investigational drugs were screened using a high-throughput screening (HTS) assay ([@B55]). Among these, 23 compounds were confirmed to possess an IC~50~ below 15 μM. Three of them, including temoporfin, niclosamide, and nitazoxanide, could inhibit with an IC~50~ of 1.1 ± 0.1, 12.3 ± 0.6, 15.9 ± 0.9 μM and CC~50~ of 40.7 ± 0.7, 4.8 ± 1.0, 77 ± 7.2 μM in A549 cells, respectively \[[Figure 3](#F3){ref-type="fig"}(10,30,31) and [Table 3](#T3){ref-type="table"}; [@B3]). Temoporfin was tested in a viremia mouse model and a lethal mouse model, and it was able to inhibit viremia and protect 83% of the mice; the mice that survived did not present any signs of neurological disorder ([@B55]). These compounds inhibit the interaction between NS3 and the NS2B N-terminal fragment. By using an e-pharmacophore-based virtual screening assay, BAS 19192837 was chosen as a potent Zika NS2B-NS3 protein inhibitor \[[Figure 3](#F3){ref-type="fig"}(32)\]. However, the experimental data of the IC~50~ about this inhibitor was not shown ([Table 3](#T3){ref-type="table"}; [@B95]).

Berberine, an FDA-approved drug against DENV, has shown high binding affinity of 5.8 kcal/mol, and it binds around the active site of the receptor \[[Figure 3](#F3){ref-type="fig"}(33) and [Table 3](#T3){ref-type="table"}; [@B97]\]. Niclosamide, an FDA-approved category B anthelmintic drug for treating worm infections in both humans and domestic livestock, inhibited all three strains of ZIKV, which was measured by intracellular ZIKV RNA levels with IC~50~ values of 1.72 μM in SNB-19 cells ([@B118]). PHA-690509, an investigational compound that functions as a cyclin-dependent kinase inhibitor (CDKi), inhibited three stains with IC~50~ values of 0.37 μM as measured by intracellular ZIKV RNA levels in SNB-19 cells ([@B118]). According to experimental results, the mechanism of these two compounds occurs at post-entry stage, likely at the viral RNA replication step ([@B118]). Suramin \[[Figure 3](#F3){ref-type="fig"}(8)\], an approved polyanion antiparasitic drug, can be a potential inhibitor of Zika virus complex NS2B/NS3 proteinase with IC~50~ of 47 μM ([Table 2](#T2){ref-type="table"}; [@B19]). Computational analysis showed that suramin suppressed NS2B/NS3 proteinase activity by blocking catalytical Ser135 residue and interacting with the catalytical histidine residue ([@B19]). Erythrosin B \[[Figure 3](#F3){ref-type="fig"}(34)\], a pregnancy category B food additive, inhibited ZIKV replication by targeting NS2B-NS3 proteases with an IC~50~ of 0.62 ± 0.12 μM in A549 cells ([Table 3](#T3){ref-type="table"}) via a non-competitive mechanism by enzymatic kinetic experiments ([@B58]). Erythrosin B can also inhibit ZIKV RNA synthesis and protein expression in ZIKV-relevant neural progenitor and human placental cells ([@B58]).

Two inhibitors were tested to inhibit NS2B-NS3 protease activity with IC~50~ values of 5.2 and 4.1 μM by blocking the active site of ZIKV NS2B-NS3 protease in docked conformation ([@B49]). Five polyphenol compounds, including luteolin, astragalin, rutin, epigallocatechin gallate, and gallocatechin gallate from flavone and flavonol, inhibited ZIKV replication with IC~50~ values ranging from 22 ± 0.2 to 112 ± 5.5 μM \[[Figure 3](#F3){ref-type="fig"}(35--39) and [Table 3](#T3){ref-type="table"}; [@B59]\].

### ZIKV Inhibitors Targeting NS5 {#S3.SS2.SSS2}

Zika virus NS5 is a relative conserved large protein among members of the genus, containing an MTase domain and an RNA polymerase (RdRp) domain connected by a 10 residues linker. ZIKV NS5 can be used as a template for genome replication with an efficiency similar to that of an RNA template ([@B63]). In one study, ZIKV NS5 could extend an RNA primer annealed to an RNA template in an Mn^2+^-dependent manner, as opposed to Mg^2+^ ([@B63]). ZINC64717952 and ZINC39563464 can interact with NS5 by enzyme--ligand interactions under virtual conditions to inhibit ZIKV propagation, but no clear data about IC~50~ and CC~50~ have been reported \[[Figure 3](#F3){ref-type="fig"}(40,41) and [Table 3](#T3){ref-type="table"}; [@B92]\].

Baicalein \[[Figure 3](#F3){ref-type="fig"}(42)\], a flavonoid analog, could downregulate ZIKV replication up to 10 h post-infection, while prophylactic effects were evident in pretreated Vero cells with IC~50~ ≈ 0.004 μM and selectivity index (SI) ≈ 105,000 ([Table 3](#T3){ref-type="table"}; [@B82]). It also has antiviral activity against DENV, chikungunya virus (CHIKV), and influenza virus ([@B122]; [@B70]; [@B42]; [@B81]). DMB213 \[[Figure 3](#F3){ref-type="fig"}(43) and [Table 3](#T3){ref-type="table"}\] is a pyridoxine-derived non-nucleoside small-molecule inhibitor with an IC~50~ of 5.2 μM ([@B117]). This compound inhibits ZIKV by blocking RNA synthesis reactions catalyzed by recombinant ZIKV NS5 polymerase ([@B117]). A nuclear import inhibitor, *N*-(4-hydroxyphenyl) retinamide \[[Figure 3](#F3){ref-type="fig"}(44) and [Table 3](#T3){ref-type="table"}\], can block the interaction between high nanomolar affinity ZIKV NS5 and the host cell importin α/β1 heterodimer ([@B113]). 7-deaza-2′-C-methyladenosine (7DMA) \[[Figure 3](#F3){ref-type="fig"}(45)\], an inhibitor of hepatitis C virus polymerase ([@B80]), could inhibit ZIKV strain MR766 with CC~50~ \> 357 μM and an IC~50~ of 20 ± 15 μM in a CPE reduction assay and 9.6 ± 2.2 μM in a virus yield reduction assay in Vero cells (African Green monkey kidney cells; ECACC) ([Table 3](#T3){ref-type="table"}; [@B126]). *In vivo*, 7DMA also reduced viremia (between day 3 and 8 post infection) and delayed virus-induced morbidity and mortality in AG129 (IFN-α/β and IFN-γ receptor knockout) mice infected with ZIKV ([@B126]). Sofosbuvir \[[Figure 3](#F3){ref-type="fig"}(46)\], an FDA-approved nucleotide polymerase inhibitor, can efficiently inhibit replication and infection of several ZIKV strains, including African and American isolates, with IC~50~ values of 1--5 μM and CC~50~ \> 200 μM in Huh-7 and Jar human placental choriocarcinoma cells ([Table 3](#T3){ref-type="table"}; [@B9]). In addition, oral treatment with sofosbuvir also protected against ZIKV-induced death in 5-week-old C57BL/6J mice ([@B58]).

Using virtual screening, Stephen et al. identified four top-scoring ligands from the 28,341 compounds, including F3043-0013, F0922-0796, F1609-0442, and F1750-0048, against ZIKV with IC~50~ values of 4.8 ± 2.3, 12.5 ± 7.4, 17.5 ± 8.4, and 17.6 ± 3.1 μM, respectively, by plaque reduction assay (PRA) \[[Table 3](#T3){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}(47--50); [@B105]\]. These compounds may cooperatively interact with the hydrophobic binding pocket, extending to the S-adenosyl homocysteine (SAH) binding pocket ([@B105]). Based on the modeling of the catalytic domain of ZIKV RNA-dependent RNA polymerase (RdRpC), Ligand 6 \[(S)-2-(3-hydroxyphenyl)-*N*-(1,2,3,4-tetrahydronaphthalen-1yl)acetamide\] (ZINC50166190) was chosen as potentially having inhibitory activity against ZIKV RdRpC protein by acting as a GTP-nucleotide analog to prevent initiation of ZIKV RNA polymerization \[[Figure 3](#F3){ref-type="fig"}(51) and [Table 3](#T3){ref-type="table"}; [@B101]). Some ribonucleotide 5′-triphosphate analogs like 2′-C-Me-UTP, 2′-F-2′-CMe-UTP, 2′-C-ethynyl-UTP, and 3′-dUTP inhibit ZIKV replication with IC~50~s of 5.78, 90.76, 0.46, and 0.67 μM \[[Figure 3](#F3){ref-type="fig"}(52--55) and [Table 3](#T3){ref-type="table"}\], respectively, as measured in the presence of 1 μM competing UTP by an alternative non-radioactive coupled-enzyme assay ([@B63]). One of the major inhibitory mechanisms of ribonucleotide 5′-triphosphate against ZIKV infection is its direct termination of viral RNA polymerases ([@B63]). Merimepodib (MMPD, VX-497) \[[Figure 3](#F3){ref-type="fig"}(56)\], a potent inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH), inhibited ZIKV RNA replication with an IC~50~ of 0.6 ± 0.2 μM and IC~90~ of 1.0 ± 0.2 μM in Huh7 cells. In the cytotoxicity assay, the CC~50~ was determined to be \>10 μM, which resulted in the selective index \> 17 μM ([Table 3](#T3){ref-type="table"}; [@B107]). TLR7/8 agonist R848 (resiquimod) (toll-like receptor (TLR) agonists) inhibited ZIKV RNA synthesis in CHME3, a transformed microglial cell-line \[[Figure 3](#F3){ref-type="fig"}(57) and [Table 3](#T3){ref-type="table"}; [@B109]).

Other Small-Molecule Inhibitors With Undefined Mechanisms {#S3.SS3}
---------------------------------------------------------

AV-C(1-(2-fluorophenyl)-2-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1,2-dihydrochromeno\[2,3-c\]pyrrole-3,9-dione) \[[Figure 3](#F3){ref-type="fig"}(58)\], an interferon-activating agonist of the TRIF pathway, inhibited replication of ZIKV (IC~90~) of 5.815 μM by activating innate- and interferon-associated responses, and the CC~50~ values are well below dosages observed to induce detectable cytotoxicity of THF cells ([Table 4](#T4){ref-type="table"}; [@B90]). Along with Selenium, a free-form amino acid sequence (FFAAP) comprising glycine, cystine, and a glutamate source inhibited ZIKV replication with an ED~90~ (effective dose at which 90% of a dose of Zika virus was inhibited) of 2.5 mM in human JEG-3 cells and 4 mM in Vero cells ([Table 1](#T1){ref-type="table"}; [@B110]). Histone H3K27 methyltransferases EZH2 and EZH1 (EZH2/1) can suppress gene transcription via propagation of repressive H3K27me3-enriched chromatin domains ([@B64]; [@B24]; [@B44]). GSK926 \[[Figure 3](#F3){ref-type="fig"}(59)\], an inhibitor of histone methyltransferases EZH2/1 ([@B111]), can suppress not only DNA viruses, like herpes simplex virus (HSV) and human cytomegalovirus (adenovirus) infection, but also an RNA virus, like ZIKV replication, in human foreskin fibroblast (HFF) cells ([Table 4](#T4){ref-type="table"}; [@B2]). However, no IC~50~ was reported. T-705 (favipiravir) \[[Figure 3](#F3){ref-type="fig"}(60)\], a broad-spectrum antiviral with effects against many viruses, and a structural analog, T-1105, inhibited ZIKV strain SZ01 with an IC~50~ of 110.9 ± 13.1 and 97.5 ± 6.8 μM, respectively, and CC~50~ \> 3000 μM in Vero cells ([Table 4](#T4){ref-type="table"}; [@B11]). Emricasan \[[Figure 3](#F3){ref-type="fig"}(61)\], a pan-caspase inhibitor, inhibited ZIKV-induced increases in caspase-3 activity with IC~50~ values of 0.13--0.9 μM in SNB-19 cells against three ZIKV strains: FSS13025 (2010 Cambodian strain), MR766 (1947 Ugandan strain), and PRVABC59 (2015 Puerto Rican strain; [Table 4](#T4){ref-type="table"}; [@B118]). In addition, in Caspase-3/7 assay, Emricasan also reduced the total number of active (cleaved) caspase-3-expressing forebrain-specific hNPCs (human cortical neural progenitor cells) in both the monolayer and 3-dimensional organoid cultures infected by ZIKV FSS13025 strain ([@B118]). Two halogenated chrysins, FV13 and FV14 \[[Figure 3](#F3){ref-type="fig"}(62,63)\], inhibited ZIKV infection with an IC~50~ of 1.65 ± 0.86 and 1.39 ± 0.11 μM in LLC/MK2 cells, respectively ([@B106]). The CC~50~s to the LLC/MK2 cell-based system of FV13 and FV14 were 44.28 ± 2.90 and 42.51 ± 2.53 μM, respectively ([Table 4](#T4){ref-type="table"}; [@B106]). The investigations into the mechanism of these two halogenated chrysin actions suggested multiple targets, but maximal efficiency was achieved with early post-infection treatment ([@B106]). Compound 1 was confirmed with an inhibitor of ZIKV-induced cytopathic effect (CPE) with an IC~50~ of 5.95 μM and a CC~50~ of 100 μM in human fetal neural stem cells (NSCs) \[[Figure 3](#F3){ref-type="fig"}(64) and [Table 4](#T4){ref-type="table"}; [@B7]). PKI 14-22 (PKI) \[[Figure 3](#F3){ref-type="fig"}(65)\], a PKA inhibitor, could act as a potent inhibitor of Asian/American and African lineages of ZIKV replication with an IC~50~ of about 20 μM in endothelial cells and astrocytes by minimal cytotoxicity ([Table 4](#T4){ref-type="table"}; [@B17]). Cavinafungin \[[Figure 3](#F3){ref-type="fig"}(66)\], targeting ER signal peptidase by binding on SEC11, inhibited ZIKV replication with an IC~50~ of 150 nM and CC~50~ of 1650 nM in A549 cells ([Table 4](#T4){ref-type="table"}; [@B29]). Manidipine and cilnidipine, voltage-gated Ca^2+^ channel (VGCC) inhibitors, could inhibit ZIKV infection by 100% with no plaque formation observed at a concentration of 10 μM in Vero cells ([@B113]). According to accumulating data, benidipine hydrochloride, pimecrolimus, and nelfinavir mesylate can also inhibit ZIKV replication with a concentration of 10 μM in Vero cells \[[Table 4](#T4){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}(67--69); [@B113]\]. Five 2′-C--methylated derivatives of nucleoside analog \[nucleosides with a methyl moiety at the 2′-C position of the ribose ring, including 2′-CMA,7-deaza-2′-CMA, 2′-CMC, 2′-CMG, and 2′-CMU \[[Figure 3](#F3){ref-type="fig"}(70--74)\], can reduce the viral titer with an IC~50~ of 5.26 ± 0.12 μM for 2′-CMA, 8.92 ± 3.32 μM for 7-deaza-2′-CMA, 10.51 ± 0.02 μM for 2′-CMC, 22.25 ± 0.03 μM for 2′-CMG, and 45.45 ± 0.64 μM for 2′-CMU in Vero cells ([Table 4](#T4){ref-type="table"}; [@B30]). All these nucleoside analogs showed weak or no cytotoxic effects at a concentration of 100 μM on cell proliferation ([@B30]). NGI-1 \[[Figure 3](#F3){ref-type="fig"}(75)\], an aminobenzamide-sulfonamide compound targeting both oligosaccharyltransferase OST isoforms, can block viral RNA replication significantly to inhibit viral particle formation with an IC~50~ of 2.2 μM in HEK293 cells ([Table 4](#T4){ref-type="table"}; [@B91]). Nordihydroguaiaretic (NDGA) and its methylated derivative, tetra-*O*-methyl nordihydroguaiaretic acid (M4N), disturbed lipid metabolism and sterol regulatory element-binding proteins (SREBP) \[[Figure 3](#F3){ref-type="fig"}(76--77)\], thereby inhibiting ZIKV PA259459 isolated from a patient with an IC~50~ of 9.1 μM and SI of 17.8 and IC~50~ of 5.7 μM and SI of 187.9, respectively ([Table 4](#T4){ref-type="table"}; [@B68]). Obatoclax, SaliPhe, and gemcitabine affected ZIKV-mediated transcription \[[Figure 3](#F3){ref-type="fig"}(78--80) and [Table 4](#T4){ref-type="table"}\], translation, and posttranslational modifications as well as metabolic pathways, by different mechanisms of action, inhibiting ZIKV infection at non-cytotoxic concentrations ([@B47]). ZMP STE24, when complexed with proteins of the interferon-induced transmembrane protein (IFITM) family by co-immunoprecipitation studies, inhibited ZIKV viral titer in T98-G cells ([Table 1](#T1){ref-type="table"}; [@B33]). PHA-690509 \[[Figure 3](#F3){ref-type="fig"}(81)\], an investigational compound that functions as a CDKi, inhibited three ZIKV stains with IC~50~ values of 0.37 μM, as measured by intracellular ZIKV RNA levels in SNB-19 cells ([Table 3](#T3){ref-type="table"}; [@B118]).

###### 

Other small-molecule inhibitors with undefined mechanisms.

  **Number of chemical structures in [Figure 3](#F3){ref-type="fig"}**   **Inhibitor**              **Testing model**   **Cell lines**                  **IC~50~ (μM)**   **CC~50~ (μM)**   **References**
  ---------------------------------------------------------------------- -------------------------- ------------------- ------------------------------- ----------------- ----------------- ----------------
  58                                                                     AV-C                       *in vitro*          THF cells                       --                --                [@B90]
  59                                                                     GSK926                     *in vitro*          HFF cells                       --                --                [@B111]
  60                                                                     T-705                      *in vitro*          Vero cells                      110.9 ± 13.1      \>3000            [@B11]
  61                                                                     Emricasan                  *in vitro*          SNB-19 cells                    0.13 ∼ 0.9        --                [@B118]
  62                                                                     FV13                       *in vitro*          LLC/MK2 cells                   1.65 ± 0.86       44.28 ± 2.90      [@B106]
  63                                                                     FV14                       *in vitro*          LLC/MK2 cells                   1.39 ± 0.11       42.51 ± 2.53      [@B106]
  64                                                                     Compound 1                 *in vitro*          Human fetal neural stem cells   5.95              100               [@B7]
  65                                                                     PKI 14-22                  *in vitro*          Endothelial cells               20                --                [@B17]
  66                                                                     Cavinafungin               *in vitro*          A549 cells                      150               1650              [@B29]
  67                                                                     Benidipine hydrochloride   *in vitro*          Vero cells                      --                --                [@B113]
  68                                                                     Pimecrolimus               *in vitro*          Vero cells                      --                --                [@B113]
  69                                                                     Nelfinavir mesylate        *in vitro*          Vero cells                      --                --                [@B113]
  70                                                                     2′-CMA                     *in vitro*          Vero cells                       5.26 ± 0.12      --                [@B30]
  71                                                                     7-deaza-2′-CMA             *in vitro*          Vero cells                       8.92 ± 3.32      --                [@B30]
  72                                                                     2′-CMC                     *in vitro*          Vero cells                      10.51 ± 0.02      --                [@B30]
  73                                                                     2′-CMG                     *in vitro*          Vero cells                      22.25 ± 0.03      --                [@B30]
  74                                                                     2′-CMU                     *in vitro*          Vero cells                      45.45 ± 0.64      --                [@B30]
  75                                                                     NGI-1                      *in vitro*          HEK293 cells                    2.2               --                [@B91]
  76                                                                     NDGA                       *in vitro*          Vero cells                      9.1               --                [@B68]
  77                                                                     M4N                        *in vitro*          Vero cells                      5.7               --                [@B68]
  78                                                                     Obatoclax                  *in vitro*          RPE cells                       0.04 ± 0.01       2.6 ± 0.4         [@B47]
  79                                                                     SaliPhe                    *in vitro*          RPE cells                       0.05 ± 0.02       \>10              [@B47]
  80                                                                     Gemcitabine                *in vitro*          RPE cells                       0.01              \>10              [@B47]
  81                                                                     PHA-690509                 *in vitro*          SNB-19 cells                    0.37              --                [@B118]

Strategies for Developing Small-Molecule ZIKA Inhibitors {#S4}
========================================================

The development of anti-ZIKV drugs requires effective strategies. For example, using existing drug libraries to screen drug molecules that inhibit new targets is an effective method to develop new drugs ([@B119]; [@B48]). In silicon-based drug modeling, it is another economical and useful strategy to identify candidate drugs in a short amount of time ([@B83]; [@B48]). In addition, virtual screening and electronic pharmacokinetic modeling also facilitate the discovery of effective drug molecules ([@B95]). First, the virtual screening method based on electronic pharmacodynamics was adopted to screen effective inhibitors of ZIKV NS2B-NS3 protein from the ASINE database (including 467,802 molecules) ([@B95]). Then, the complexes of known NS2B-NS3 protein and its inhibitor were used to establish a five-featured pharmacophore hypothesis, ADDRR, which consists of one hydrogen bond acceptor (A), two hydrogen bond donors (D), and two aromatic rings (R) ([@B95]). The pharmacophore model was verified by enrichment analysis before the virtual screening process ([@B95]).

Active development of screening methods to assess the antiviral activity of compounds is a key step in the discovery of new drugs ([@B27]). Virus replication relies on cellular mechanisms, which means that *in vitro* experiments use host cells for culture and virus replication. Since ZIKV can infect many different cells, multiple cell lines should be used to study ZIKV infection. The screening of effective drugs using multiple cells provides a good framework for drug discovery ([@B4]). Other strategies include RNA interference, long non-coding RNAs, miRNAs, interfering peptides, and compounds targeting viral RNA ([@B36]), underexplored building blocks, and elements introducing into medicinal chemistry ([@B77]).

Conclusion {#S5}
==========

As an arthropod-borne single-stranded positive RNA virus, ZIKV utilizes a number of host viral proteins and cellular components to accomplish its replication cycle, including the steps of viral entry, genomic replication, structural and non-structural protein processing, assembly, and budding of virions. Such actions result in a series of congenital abnormities like Guillain--Barré syndrome in adults, microcephaly in newborns, and fetal demise during pregnancy ([@B25]), and the viral and host proteins involved in the virus life cycle can serve as targets for development of small-molecule ZIKV inhibitors. For example, the ZIKV E protein is responsible for the binding of the virus to host cell receptors and mediating viral entry into the host cell; therefore, some small molecule inhibitors targeting the ZIKV E protein are effective in inhibiting virus attachment and entry ([@B10]; [@B31]; [@B82]). AXL expressed on human glial cells can permit ZIKV binding and entry into the host glial cells ([@B78]; [@B67]) and small molecule compounds targeting AXL may be effective in inhibiting ZIKV infection ([@B93]). However, any compounds targeting host proteins may affect their normal functions and cause adverse effects.

Study has shown that, since the stem region of the ZIKV E protein has high sequence similarity to that of other flavivirues, such as DENV and yellow fever virus (YFV), the ZIKV inhibitor targeting this region is also highly effective against DENV and YFV infection ([@B120]). Therefore, it is essential to develop small molecule compounds with broad flavivirus inhibitory activity. Another important strategy is to develop small molecule ZIKV inhibitors targeting the different steps of ZIKV replication cycle with a synergistic antiviral effect when they are used in combination.

Numerous cases of ZIKV sexual transmission have been reported during recent ZIKV outbreaks, and studies have shown that ZIKV also replicates in human prostate cells ([@B104]). However, little is known about what viral protein(s) and host factor(s) are involved in this event. Therefore, it is essential to identify these proteins as targets for development of small-molecular inhibitors for preventing sexual transmission of ZIKV.

With the increasing understanding of viral protein structure, tremendous progresses have been made in structure-based discovery of inhibitors targeting the structure and non-structure protein of ZIKV, such as the E protein, three NS2B-NS3 proteinase constructs and helicase, NS5 methyltransferase and polymerase. Several series of small-molecule ZIKV inhibitors targeting these proteins have been reported. However, most of them were tested *in vitro* while only a small percentage of these compounds have been evaluated in animal models *in vivo*, and very few have advanced into clinical trials. Therefore, further studies should focus on exploiting novel strategies to identify new anti-ZIKV compounds, elucidating their mechanisms of action, improving the efficacy of anti-ZIKV compounds, and evaluating the *in vivo* efficacy and safety of these compounds in suitable animal models and patients. Further development of small-molecule ZIKV inhibitors with high-efficiency and low toxicity will bring promise for clinic treatment of ZIKV infection and related diseases in the near future.

Author Contributions {#S6}
====================

LW, RL, YG, YL, XD, RX, YZ, and FY drafted the manuscript. TY, SJ, and FY revised and edited the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by grants from the National Natural Science Foundation of China (81974302 and 81601761), Hebei Province's Program for Talents Returning from Studying Overseas (CN201707), a starting grant from Hebei Agricultural University (ZD2016026 and YJ201843), and the Program for Youth Talent of Higher Learning Institutions of Hebei Province (BJ2018045).

[^1]: Edited by: Lijun Rong, University of Illinois at Chicago, United States

[^2]: Reviewed by: Gong Cheng, Tsinghua University, China; Liying Ma, China CDC NAIDS, China

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Virology, a section of the journal Frontiers in Microbiology
